Japan’s MHLW Issues Warning To Janssen Regarding Xeplion Deaths
This article was originally published in PharmAsia News
Executive Summary
After a string of deaths in Japan related to Janssen’s antipsychotic drug Xeplion (paliperidone), the MHLW issued the company a warning, instructing it to add limited dose recommendations to package inserts and inform medical institutions of the situation.